Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bivalent oral poliovirus vaccine (bOPV) is a live-attenuated vaccine containing Sabin strains of poliovirus types 1 and 3. It was developed to replace the trivalent oral poliovirus vaccine (tOPV) in routine immunization programs following the global eradication of wild poliovirus type 2, thereby reducing the risk of vaccine-associated paralytic poliomyelitis (VAPP) and circulating vaccine-derived polioviruses (cVDPV) associated with the type 2 component. The University of Chile has been involved in Phase 4 clinical research (such as the IPV 002ABMG study) to evaluate the effectiveness of sequential immunization schedules combining inactivated poliovirus vaccine (IPV) and bOPV. These studies aim to optimize humoral and intestinal immunity to prevent both individual disease and community transmission.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bivalent oral poliovirus vaccine (Universidad de Chile).